Integer Holdings Corporation · NYSE:ITGR
Integer — Greatbatch — Investor Day (March 2011)
15 slides from Integer's investor day presentation, Mar 24, 2011
Slide 1: Greatbatch Innovation: Opening new pathways to growth
~ ® Greatbatch INNOVATSON Opening new pathways to growth.
Slide 2: Tom Mazza, Senior Vice President, Chief Financial Officer
Tom Mazza Senior Vice president Chief Financial officer 2
Slide 3: Medical Device Evolution
3 Medical Device Evolution
Slide 4: Financial impact on Greatbatch
Financial impact on greatbatch Designed to raise growth and profitability profile Driving sales through OEM partners Improved gross and adjusted operating income margins Sale of distribution rights and/or license fees Evolving profitability in 2011 and growing in out-years Cardiovascular product con
Slide 5: Medical device strategy drives improved revenue growth
Medical device strategy drives improved revenue growth (CHART)
Slide 6: Device R&D and Revenue
(CHART) Device R&D and REVENUE Approx. $25mm Core Business R&D $4 $20 $13 $10 $35 $20 $25 $10 $20 $65 $10 R&D Investment in New Device Projects ($mm)
Slide 7: R&D and Adjusted operating income trends
R&D and Adjusted operating income trends (CHART)
Slide 8: Free cash flow & debt reduction
Free cash flow & debt reduction (CHART) (CHART)
Slide 9: Guidance - Fiscal 2011
GUIDANCE - FISCAL 2011 Total revenue: $540 mm - $560 mm CRM & Neuromodulation: Flat Vascular Access: 10% - 20% Orthopaedic: 2% - 10% Electrochem: 2% - 5% Adjusted operating margin: 12% -13%(1) Adjusted diluted EPS: $1.55 - $1.65(2) (1) Excludes $8 - $11 million of non-recurring, unusual or infrequen
Slide 10: Long-term objectives
LONG-TERM objectives Revenue growth: 2% core +5% over core growth from new products Higher gross margins R&D: 8.5% - 9.0% of revenues +50 to 100 bps/year of adjusted operating margin improvement Mid-teens adjusted operating income margin on trajectory towards 20%
Slide 11: Thomas Hook, President & CEO
Thomas Hook President & CEO 11
Slide 12: What to expect: near-term and longer-term
NEAR-TERM Incremental revenues from new Cardiovascular products Announcements about new Cardiovascular approvals and partnering agreements Conduct Algostim product evaluations & testing LONGER-TERM Achievement of major development & commercial milestones Announcements on additional innovations and N
Slide 13: Review of QiG milestones
Review of QiG milestones Review of QiG milestones 13
Slide 14: Key Takeaways
KEY TAKEAWAYS A natural evolution of our capabilities Founded on a disciplined, diversified portfolio approach Greatbatch has been executing on this strategy for three years Solidifies & deepens our partnerships with current customers Funded internally from strong cash flow generation Designed to ra
Slide 15: Greatbatch Innovation: Opening new pathways to growth
” * Greatbatch INNOVATSON Opening new pathways to growth.